Familial Mediterranean fever: a critical digest of the 2012-2013 literature.
The year 2012-2013 has been a fertile one in the area of FMF inquiry. Recent studies have led to further insight into the possible mechanisms whereby pyrin mutations might cause the auto-inflammatory phenotype that is characteristic of FMF. Evidence-based guidelines for diagnosis of FMF, including the role of genetic testing, have become available. Risks for colchicine resistance have been partially defined, and a randomised, controlled trial showing efficacy of an interleukin-1 antagonist for treatment of colchicine-resistant or intolerant FMF patients was reported. In this review, we summarise these and other salient findings from the recent FMF literature, and discuss their significance for the clinician.
Department of Pediatrics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. eisenstein@hadassah.org.il.
Eli M
EM
Eisenstein
Yakov
Y
Berkun
Eldad
E
Ben-Chetrit
D000818:Animals; D015897:Comorbidity; D010505:Familial Mediterranean Fever / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D011237:Predictive Value of Tests; D011379:Prognosis; D012307:Risk Factors
D007166:Immunosuppressive Agents